Enzo Biochem, Inc.
ENZ was delisted on the 17th of April, 2025.
39 hedge funds and large institutions have $23.1M invested in Enzo Biochem, Inc. in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 11 closing their positions.
385% more call options, than puts
Call options by funds: $165K | Put options by funds: $34K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less funds holding
Funds holding: 47 → 39 (-8)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
33% less capital invested
Capital invested by funds: $34.7M → $23.1M (-$11.5M)
64% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Potomac Capital Management
New York
|
+$611K |
| 2 |
SC
Shay Capital
New York
|
+$94.2K |
| 3 |
Morgan Stanley
New York
|
+$12.1K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.36K |
| 5 |
C
Covestor
London,
United Kingdom
|
+$5.98K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$1.81M |
| 2 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
-$1.25M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$639K |
| 4 |
Renaissance Technologies
New York
|
-$224K |
| 5 |
FLC
Fifth Lane Capital
Austin,
Texas
|
-$156K |
ENZ Hedge Fund Activity: Q3 2023 in Review
39 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q3 2023, worth a combined $23.1M — down 33% from $34.7M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ENZ and 4 opened new positions — a net loss of 7 holders — while 9 trimmed existing stakes and 7 added.
The largest buyer was Potomac Capital Management, adding an estimated $611K. The largest seller was Fuller & Thaler Asset Management, exiting entirely with an estimated $1.81M sold.
- 39 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q3 2023, down from 47 in Q2 2023.
- Funds reported $23.1M of Enzo Biochem, Inc. stock for Q3 2023, down 33% quarter-over-quarter.
- 4 funds opened new Enzo Biochem, Inc. positions in Q3 2023 and 11 closed out, a net change of -7 holders.
- The largest Enzo Biochem, Inc. buyer in Q3 2023 was Potomac Capital Management, an estimated $611K added.
- The largest Enzo Biochem, Inc. seller in Q3 2023 was Fuller & Thaler Asset Management, an estimated $1.81M sold.
Based on aggregated 13F filings for Q3 2023.